Diametric Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Diametric Capital’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,314	Closed	-$31.2K	–	433
2023 Q1	$31.2K	Buy	+14,314	New	+$45.5K	0.02%	317

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Diametric Capital's ORMP Position: Q2 2023 in Review

Diametric Capital sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 14,314 shares — an estimated $31.2K sold.

Diametric Capital first reported a position in ORMP in Q1 2023 and held it in 1 quarter. The position peaked at $31.2K in Q1 2023. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

Diametric Capital reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Diametric Capital sold 14,314 Oramed Pharmaceuticals shares in Q2 2023, an estimated $31.2K.
Diametric Capital first reported a position in Oramed Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Diametric Capital's Oramed Pharmaceuticals position peaked at $31.2K in Q1 2023.
50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Diametric Capital's 13F filing for Q2 2023, filed 11 Aug 2023.